DaVita stock
DVANYSEDaVita Inc., HealthcareISIN US23918K1088
67Score 67 out of 100, Neutral
Price and trend
72 / 100
Price history
+50% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 1.8% above it.
Since March 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 48).
The price is 24% below its 52-week high. Largest decline in 20 years: 51% (August 2021 to November 2022).
Chart figures for advanced users
- SMA 50$182.90
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$180.23
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)48
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$103.87
- The lowest closing price of the last twelve months.
- Resistance$240.96
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- DaVita Inc. belongs to the Medical (Care Facilities) industry (United States) and, with a market value of $11.54B, is number 10 of 56 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $13.64B (up 6.5% year on year) and earnings of $746.8M (down 20.2%).
- For fiscal 2026, analysts expect on average revenue of $14.18B (up 4%) and adjusted earnings per share of $14.70 (up 35.4%).
Show more
- MEQIRI Score 67 out of 100 (Neutral): rank 183 of 714 in Healthcare, median 53.
- The P/E is 13.8 (Medical (Care Facilities) median 19.4, own median of recent years 13.7).
- Our model puts fair value at $280.48, with the price 35% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Share buybacksShare count down 28% since 2020.Capital allocation 76
- Consistently profitableProfit in all 10 fiscal years from 2016 to 2025.Fundamentals 90
- Earnings turn into cashFree cash flow 141% of earnings over the last 12 months.Fundamentals 90
Weaknesses
- Volatile share priceVolatility 47% a year over the last 12 months.Stability 39
Its standout strengths are fundamentals and valuation, while stability holds the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 65 to 67.
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- high price swings
What lowers it
- solid fundamentals
Valuation
Valuation signal
Possible value trapIn our model the price counts as cheap below $200.34 and expensive above $467.47 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $303.81 (cash-flow model) and $257.15 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 9.3%. At 10.3% the fair value would be $258.29, at 8.3% it would be $312.52.
Possible value trap: looks cheap, but high risk.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (19.4).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 6.4% on the twelve months before. Revenue has grown solidly since 2006, at about 6% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 27%, operating 15%, net 5%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 1 Feb 2027in 81 days
- Last reported
- 29 Oct 2026EPS reported $3.82 (expected $3.57)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $14.70−0.8%
- Revenue
- $14.18B+0.6%
- Earnings per share
- $16.65−1.8%
- Revenue
- $14.66B+0.9%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −19.3%Guidance for adjusted operating income (midpoint $2.2 billion) and adjusted EPS (midpoint $14.65) reaffirmed, with treatment volumes now expected near the top end of the range.
“For the full year, we are reiterating our adjusted operating income guidance range with a midpoint of $2.2 billion and our adjusted earnings per share guidance range with a midpoint of $14.65.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 4 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 4 insiders sold, $126.19M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Berkshire Hathaway IncSale
27 Oct 2026, Major holder
- Shares
- 382,563
- Price
- $180.43
- Value
- $69.03M
- Berkshire Hathaway IncSale
31 Jul 2026, Major holder
- Shares
- 182,980
- Price
- $199.55
- Value
- $36.51M
- Rodriguez JavierSale
16 Jun 2026, Chief Executive Officer
- Shares
- 39,407
- Price
- $209.28
- Value
- $8.25M
Show 3 more
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at DaVita
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 67
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Care Facilities)
The next larger and next smaller companies by market value
- Apollo Hospitals EnterpriseAPOLLOHOSP.NS $13.2B70
- Aier Eye Hospital Group300015.SZ $12.08B66
- Fresenius Medical Care AG & Co. KGaAFME.DE $11.78B59
- Universal Health ServicesUHS $11.57B73
- Ensign GroupENSG $10.86B66
- Max Healthcare InstituteMAXHEALTH.NS $9.64B53
- PACS GroupPACS $7.95B67
- ChemedCHE $7.17B75
ETFs that hold DaVita
Held by 37 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Ageing Population UCITS ETF2B77 | 0.47% | 0.40% | €807M |
| Xtrackers S&P 500 Equal Weight UCITS ETF 2C EUR HedgedXDEE | 0.21% | 0.30% | €14.88B |
| Invesco Global Buyback Achievers UCITS ETFBBCK | 0.14% | 0.39% | €188.08M |
Show 5 more
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.10% | 0.30% | €944.34M |
| State Street SPDR S&P U.S. Health Care Select Sector UCITS ETF (Acc)ZPDH | 0.10% | 0.15% | €592.11M |
| iShares S&P 500 Health Care Sector UCITS ETFQDVG | 0.09% | 0.15% | €3.27B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.08% | 0.43% | €2.48B |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.06% | 0.45% | €1.53B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 4 Nov 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.